Drew Deniger - Mar 29, 2022 Form 3 Insider Report for Alaunos Therapeutics, Inc. (TCRT)

Role
VP, Research & Development
Signature
/s/ Drew Deniger
Stock symbol
TCRT
Transactions as of
Mar 29, 2022
Transactions value $
$0
Form type
3
Date filed
4/8/2022, 04:30 PM
Next filing
Sep 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TCRT Common Stock 15K Mar 29, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCRT Employee Stock Option (right to buy) Mar 29, 2022 Common Stock 50K $4.13 Direct F1
holding TCRT Employee Stock Option (right to buy) Mar 29, 2022 Common Stock 30K $4.72 Direct F2
holding TCRT Employee Stock Option (right to buy) Mar 29, 2022 Common Stock 75K $2.82 Direct F3
holding TCRT Employee Stock Option (right to buy) Mar 29, 2022 Common Stock 35K $4.31 Direct F4
holding TCRT Employee Stock Option (right to buy) Mar 29, 2022 Common Stock 250K $1.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on September 24, 2019. One-fourth of the shares underlying the option vested on September 24, 2020, and the remainder vests in twelve successive equal quarterly installments measured from September 24, 2020, subject to the Reporting Person's continued service through each such date.
F2 The option was granted on December 31, 2019. One-twelfth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.
F3 The option was granted on January 4, 2021. One-twelfth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.
F4 The option was granted on March 4, 2021. One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after December 31, 2020, subject to the Reporting Person's continued service through each such date.
F5 The option was granted on October 29, 2021. One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.